Vraylar

Schizophrenia, Bipolar Disorder, Bipolar Disorder + 1 more
Treatment
20 Active Studies for Vraylar

What is Vraylar

CariprazineThe Generic name of this drug
Treatment SummaryCariprazine is a medication used to treat schizophrenia and bipolar disorder. It works by activating dopamine receptors in the brain to reduce symptoms of these conditions. Cariprazine is different from other antipsychotic medications because it specifically targets certain dopamine receptors. It was approved by the FDA in 2015 and can also be used as an additional treatment for major depressive disorder.
Vraylaris the brand name
image of different drug pills on a surface
Vraylar Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Vraylar
Cariprazine
2015
6

Effectiveness

How Vraylar Affects PatientsCariprazine is an antipsychotic drug that has been used to reduce symptoms of schizophrenia and bipolar I disorder in clinical trials. Studies have also found it to be effective in treating anxiety and low mood. It works by binding to dopamine receptors, though it does so in a way that causes fewer side effects (such as restlessness and tremors) than other antipsychotics. Additionally, it has an effect on serotonin receptors that helps reduce the risk of side effects even further. However, there is still a risk of side effects with cariprazine, such as akathisia, extrapyramidal disorder, restlessness
How Vraylar works in the bodyCariprazine is a drug used to treat schizophrenia and bipolar disorder. It works by targeting dopamine receptors, which are involved in reward processing and motivation. Specifically, it binds to dopamine D2 and D3 receptors, which are associated with positive and negative symptoms of schizophrenia. It also binds to other receptors in the body, which have been linked to pro-cognitive and antidepressant effects. These effects help reduce the symptoms of schizophrenia and bipolar disorder.

When to interrupt dosage

The suggested measure of Vraylar is contingent upon the diagnosed affliction, for instance Bipolar Disorder, Acute Coryza and Schizophrenia. The amount of dosage is contingent upon the procedure of delivery featured in the table beneath.
Condition
Dosage
Administration
Mental Depression
, 1.5 mg, 3.0 mg, 4.5 mg, 6.0 mg
, Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Kit - Oral, Kit, Capsule - Oral, Capsule
Schizophrenia
, 1.5 mg, 3.0 mg, 4.5 mg, 6.0 mg
, Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Kit - Oral, Kit, Capsule - Oral, Capsule
Bipolar Disorder
, 1.5 mg, 3.0 mg, 4.5 mg, 6.0 mg
, Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Kit - Oral, Kit, Capsule - Oral, Capsule
Bipolar Disorder
, 1.5 mg, 3.0 mg, 4.5 mg, 6.0 mg
, Oral, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Kit - Oral, Kit, Capsule - Oral, Capsule

Warnings

Vraylar Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Cariprazine may interact with Pulse Frequency
There are 20 known major drug interactions with Vraylar.
Common Vraylar Drug Interactions
Drug Name
Risk Level
Description
Amisulpride
Major
Cariprazine may increase the antipsychotic activities of Amisulpride.
Azelastine
Major
Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Deutetrabenazine
Major
The risk or severity of adverse effects can be increased when Cariprazine is combined with Deutetrabenazine.
Ethanol
Major
Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Methylene blue
Major
Cariprazine may increase the serotonergic activities of Methylene blue.
Vraylar Toxicity & Overdose RiskIn one case, a patient accidentally took a high dose of cariprazine (48 mg/day) and experienced dizziness and drowsiness. They fully recovered the same day. There is no specific antidote for overdose, so medical supervision and monitoring is recommended. It is also possible that multiple drugs were involved in the overdose.
image of a doctor in a lab doing drug, clinical research

Vraylar Novel Uses: Which Conditions Have a Clinical Trial Featuring Vraylar?

171 active trials are at present assessing the capability of Vraylar to manage Bipolar Disorder, Bipolar Disorder Type I and Schizophrenia.
Condition
Clinical Trials
Trial Phases
Mental Depression
2 Actively Recruiting
Phase 2, Not Applicable
Bipolar Disorder
0 Actively Recruiting
Schizophrenia
97 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2
Bipolar Disorder
0 Actively Recruiting

Vraylar Reviews: What are patients saying about Vraylar?

5Patient Review
7/22/2022
Vraylar for Bipolar Depression
This medicine has been an absolute game-changer for me. If you're struggling with bipolar depression, I cannot recommend this highly enough. Finally, I feel free from negative thoughts and am able to lead a happy life.
5Patient Review
7/3/2022
Vraylar for Bipolar Depression
This treatment was amazing and it really gave me my life back. I would encourage anyone struggling to not give up hope because there are options out there that can help you.
5Patient Review
9/10/2022
Vraylar for Bipolar Depression
Vrylar has the strange side effect of making me a morning person. I go to bed just fine, but then I wake up feeling great and full of energy between 5 and 7am. This is even with taking Seroquel at night. I would rate this medication 10 out of 10.
5Patient Review
10/26/2022
Vraylar for Bipolar Depression
I had wonderful results from this medication, however the cost is quite high. I was only able to try it because my nurse practitioner gave me some samples, but now that I need to buy it myself it's quite out of reach. If anyone has any suggestions for dealing with the cost, please let me know.
5Patient Review
7/25/2022
Vraylar for Schizophrenia
Vraylar has been an absolute godsend. It's drastically decreased the severity and frequency of my hallucinations, both visual and auditory. Additionally, it's helped to lessen delusions and other symptoms so that I can live a relatively normal life again.
3.7Patient Review
7/24/2022
Vraylar for Bipolar Depression
I've tried a lot of different medications, and Vraylar is by far the best one for my depression. However, I have experienced some intense side effects like nausea and headaches. Hoping that these go away with time!
3.7Patient Review
7/25/2022
Vraylar for Bipolar Depression
This medication really helped to improve my mood. I felt less anxious and more even-keeled. Everything seemed brighter and easier to handle.
3.3Patient Review
8/17/2021
Vraylar for Bipolar Depression
I've been taking this for a few weeks now. It's not as effective at controlling my symptoms as Olanzapine was, but the weight gain and lethargy from Olanzapine were too much. I don't sleep well and Vraylar isn't much help for that. It took a few days for the drug to take effect but when it did it works well enough. Good thing is insurance covered the cost otherwise I would not have been able to afford.
3.3Patient Review
8/14/2022
Vraylar for Bipolar I Disorder with Most Recent Episode Mixed
At first, this treatment was working well for me. But then my anxiety started to get worse and now I'm feeling really nervous all the time.
3Patient Review
4/4/2022
Vraylar for Bipolar I Disorder with Most Recent Episode Mixed
I gained 10 lbs while on this medication, and I was always hungry. Additionally, I experienced erectile dysfunction and low interest in sex. However, I think it did help with my delusions when I first started taking it. But the side effects were too much for me to handle.
3Patient Review
11/3/2022
Vraylar for Bipolar Depression
After six weeks of taking Vraylar, I'm done. The constant flu-like symptoms were really getting me down--I was constantly tired and had no appetite. Abilify worked better for me.
2.3Patient Review
9/10/2022
Vraylar for Bipolar I Disorder with Most Recent Episode Mixed
At first, I thought this medicine was amazing. But then I started putting on a lot of weight very quickly, developed diabetes, and started to feel very apathetic from low dopamine levels. If you can, get off this medication as soon as possible.
1Patient Review
9/1/2022
Vraylar for Bipolar I Disorder with Most Recent Episode Mixed
Vraylar caused me so much anxiety and panic that it was honestly terrible. I had to stop taking the medicine because the feeling were just too intense and unbearable. It's a shame, too, because I know it works for some people.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vraylar

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What symptoms does Vraylar treat?

"The goal of this medication is to improve overall depressive and manic symptoms, as well as to treat mixed episodes— when an individual experiences symptoms of both depression and mania at the same time."

Answered by AI

What are the main side effects of Vraylar?

"The following are extrapyramidal symptoms: muscle spasms, muscle rigidity, tremor, and jerking movements. Agitation, indigestion, nausea, vomiting, sleepiness, and restlessness are also common. Weight gain is a possibility."

Answered by AI

What conditions does Vraylar treat?

"Vraylar is a drug that is approved to treat mixed or manic episodes of bipolar I disorder. The drug is also approved to treat schizophrenia, as well as bipolar depression in bipolar I disorder."

Answered by AI

Is Vraylar a mood stabilizer or antipsychotic?

"The medication Vraylar can be used as an antipsychotic or an antidepressant depending on the diagnosis. If you are prescribed Vraylar, your doctor will closely monitor you for any suicidal thoughts or behaviors."

Answered by AI

What is the drug Vraylar used for?

"Cariprazine is a medication that affects the brain in order to treat schizophrenia. It is also known as a second-generation antipsychotic (SGA) or atypical antipsychotic. Cariprazine rebalances dopamine and serotonin in order to improve thinking, mood, and behavior."

Answered by AI

How does Vraylar make u feel?

"The most common side effects of VRAYLAR include difficulty moving or slow movements, tremors, uncontrolled body movements, restlessness, sleepiness, nausea, vomiting, and indigestion."

Answered by AI

Clinical Trials for Vraylar

Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Repetitive Transcranial Magnetic Stimulation for Schizophrenia

18 - 65
All Sexes
Nashville, TN
The central hypothesis is this: DMN connectivity can be modulated with inhibitory cTBS when delivered on an accelerated treatment schedule. This study seeks to provide evidence that accelerated, network-targeted inhibitory stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cognitive performance in individuals with schizophrenia and schizoaffective disorder. This study will also compare the effect of inhibitory cTBS in healthy individuals, as it may also lead to both altered network activity and a behavioral change in cognitive performance in individuals without schizophrenia or schizoaffective disorder. If successful, this study will have identified a safe, effective, and broadly applicable treatment for cognitive impairment in schizophrenia that has potential for translation into many other psychiatric and neurodevelopmental disorders, such as autism.
Waitlist Available
Has No Placebo
Vanderbilt Psychiatric HospitalHeather Ward, MD
Image of Woodland International Research Group /ID# 275747 in Little Rock, United States.

Emraclidine for Schizophrenia

18 - 65
All Sexes
Little Rock, AR
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 258 participants will be enrolled across roughly 32 sites in the United States. Participants in Part A will be assigned to one of multiple ascending doses of emraclidine or placebo administered orally for 14 days or up to 21 days. Participants in Part B will receive Emraclidine or placebo administered orally for up to 42 days. Participants will be followed for 30 days after the last dose of the study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Phase 2
Recruiting
Woodland International Research Group /ID# 275747 (+4 Sites)ABBVIE INC.AbbVie
Have you considered Vraylar clinical trials? We made a collection of clinical trials featuring Vraylar, we think they might fit your search criteria.Go to Trials
Have you considered Vraylar clinical trials? We made a collection of clinical trials featuring Vraylar, we think they might fit your search criteria.Go to Trials
Image of Clinical Site in Richmond, United States.

Xanomeline/Trospium for Schizophrenia

18 - 40
All Sexes
Richmond, TX
This is an open label study of the treatment satisfaction, efficacy and tolerability of xanomeline/ trospium in a population of 172 participants diagnosed with schizophrenia in the early phase of illness. Participants will be followed for 24 weeks with scheduled assessments conducted by centralized raters, local mental health professionals and self-assessments completed by patients. Recruitment will be based on insufficient efficacy of previous antipsychotic or due to dissatisfaction with treatment as a result of unacceptable side effects on previous antipsychotic/patient choice, with approximately 50% for each enrollment criteria. Participants who present with both insufficient efficacy and unacceptable side effects will be considered as belonging to the insufficient efficacy subgroup. Treatment and assessments will be identical for the 2 groups. Primary outcome for participants enrolled will be improvement in overall treatment satisfaction as measured by the MSQ.
Phase 4
Waitlist Available
Clinical SiteBristol-Myers Squibb
Have you considered Vraylar clinical trials? We made a collection of clinical trials featuring Vraylar, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security